Risk Factors to Assess Prior to Starting Topical Vaginal Estrogen

Medical History Assessment

The American Heart Association recommends evaluating for history of hormone-sensitive cancers, particularly breast cancer, as this is a contraindication to systemic hormone therapy and requires careful consideration with topical estrogen 3, 4
The National Comprehensive Cancer Network suggests screening for history of endometrial cancer, as estrogen replacement therapy remains controversial in these patients despite some evidence suggesting no increased recurrence rate 5, 6
Assess for cardiovascular risk factors including history of myocardial infarction, stroke, or venous thromboembolism, as these are contraindications to systemic estrogen therapy 1, 2

Determine patient's age and time since menopause onset, as the risk profile differs based on these factors 1, 7
Identify if the patient has premature ovarian failure (before 40 years) or early menopause (before 45 years), as these conditions are associated with increased stroke risk and may influence treatment decisions 1, 2

The American College of Clinical Oncology recommends assessing for use of aromatase inhibitors, as vaginal estrogen may potentially interfere with their efficacy 3
Check for use of tamoxifen, as certain medications (paroxetine, fluoxetine) should not be offered concurrently 3

Evaluate the severity of genitourinary symptoms and previous response to non-hormonal treatments 4, 8
Consider whether the patient has had a hysterectomy, as estrogen-only formulations are appropriate for these patients while those with intact uterus require estrogen plus progesterone or bazedoxifene 1, 2

For patients with a history of endometrial cancer, determine risk of recurrence as estrogen therapy may be reasonable for those at low risk 5, 6
For breast cancer survivors, consider whether they are on aromatase inhibitors, as this affects the risk-benefit assessment of vaginal estrogen use 4, 8

Consider baseline lipid profile as menopause contributes to rising LDL and declining HDL levels 7
Monitor blood pressure as menopause can contribute to BP elevation 7

Not trying non-hormonal options thoroughly before considering hormonal therapy 4, 8
Using estradiol-containing preparations in aromatase inhibitor users without considering potential impact on circulating estradiol levels 4, 8
Failing to distinguish between systemic and topical estrogen therapy risks, as topical estrogen treatments are not associated with the same stroke risk as systemic therapy 1